Communiqués Genovis AB

Actions

GENO

SE0002485979

Equipement, fournitures et distribution médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
20,40 ^SEK	-2,63%		-2,39%	-4,00%

07/09	Synact s'envole à Stockholm, l'indice OMXS30 progresse de 0,2 %	FW
07/09	Rejlers chute sur fond de projet de fusion, l'indice OMXS30 progresse de 0,3 %	FW

Communiqués

28/07	Genovis (Q2 review): More Than Meets the P&L	AQ
23/07	Genovis AB Interim report January - June 2026	AQ
26/06	Genovis Launches AlligBAITOR™ and Strengthens Its Offering in Advanced Protein Analytics	AQ
01/06	Genovis Acquires KPL — Expanding Its Enzyme Platform with a Proprietary Portfolio of Precision Proteases for Protein Analysis	AQ
18/05	Communiqué from Genovis AB (publ) Annual General Meeting May 18, 2026	AQ
12/05	Genovis Announces Change in Chief Financial Officer Position	AQ
11/05	Genovis and MGI Tech Strengthen Collaboration to Advance RNA Sequencing Solutions	AQ
28/04	Genovis AB Interim Report January-March 2026	AQ
23/04	Genovis : Annual Report 2025 (annual report genovis 2025)	PU
23/04	Genovis AB publishes Annual Report 2025	AQ
15/04	Genovis : The board of directorsʼ proposal (genovis agm 2026 boarda proposals)	PU
15/04	Genovis : Proxy form (genovis agm 2026 proxy form)	PU
15/04	Genovis : Notice of AGM (genovis agm 2026 notice)	PU
31/03	Genovis and Plasmidsaurus Introduce SEQguard™ Dino Preserve — Enabling Ambient-Temperature RNA Shipping for Next-Generation Sequencing	AQ
25/03	Genovis Enters Non-Exclusive License Agreement for EndoS2 Enzyme Technology for Antibody-Drug Conjugate (ADC) Development and Commercialization	AQ
19/03	Genovis and Single Cell Discoveries Enter Strategic Partnership for Large-Scale Transcriptomics Analyses	AQ
11/03	Genovis : Nomination committee proposal (genovis agm 2026 nomination committee proposal)	PU
17/02	Genovis (Q4 review): Growth and a big cash pile at rapidly contracting multiples	AQ
12/02	Genovis AB Year-end Report January-December 2025	AQ
12/11	Genovis (Q3 Review) - A soft quarter ahead of a strong Q4	AQ
07/11	Genovis AB Interim report January-September 2025	AQ
17/10/25	Genovis receives order worth approximately 1 million euros from global pharmaceutical company	AQ
13/08/25	Genovis Q2 2025 - Undramatic report but recent developments are case supporting	AQ
12/08/25	Genovis AB Half-Yearly report January – June 2025	AQ
24/07/25	Genovis Expands License Agreement to Access Proprietary Enzyme Technology for Therapeutic Antibody-Drug Conjugate Development	AQ